WALTHAM, Mass., June 10, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced that SYFOVRE ® (pegcetacoplan injection) preserved visual function at 36 months in patients with ...

SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting In a prespecified ...

Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Results presented at the American Academy of Orthopaedic Surgeons Annual Meeting showed hyaluronic ...

Please provide your email address to receive an email when new articles are posted on . Intra-articular injection of amniotic membrane/umbilical cord particulate may reduce pain and improve function ...